Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
June 27, 2017 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
May 03, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
April 27, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
April 11, 2017 07:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company today reported financial results for the three months...
Agile Therapeutics to Present at 29th Annual ROTH Conference
March 01, 2017 16:10 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 14, 2017 16:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Announces Positive Top-line Phase 3 Results
January 03, 2017 16:11 ET
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...
Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer Program
December 01, 2016 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company announced today that it has received net proceeds of...
Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial
November 07, 2016 16:10 ET
|
Agile Therapeutics, Inc.
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017 Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE...